Quanterix

Quanterix Discovery Fueled by Ultra-Sensitivity Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health.

The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and enhanced treatment methods to improve the quality of life and longevity of the population fo

r generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

We'd like to wish all of our customers, collaborators, partners and employees a wonderful holiday season.
12/23/2024

We'd like to wish all of our customers, collaborators, partners and employees a wonderful holiday season.

Last night, we celebrated an incredible year at our company holiday party, filled with laughter, connection, and plenty ...
12/12/2024

Last night, we celebrated an incredible year at our company holiday party, filled with laughter, connection, and plenty of festive fun! 🎁✨
To our amazing Quanterix team: Thank you for your dedication, hard work, and passion. You’re the heart of everything we achieve, and we couldn’t do it without you.

Here’s to a joyful holiday season and an even brighter year ahead.

As we close Alzheimer’s Awareness Month, we’re highlighting the strides made in AD research. Blood biomarkers like p-Tau...
11/29/2024

As we close Alzheimer’s Awareness Month, we’re highlighting the strides made in AD research. Blood biomarkers like p-Tau 217 and cutting-edge test analysis tools are transforming dementia diagnostics. Explore our recent study to learn more: https://bit.ly/3Va0dTO

11/28/2024

Clinical trials are evolving rapidly with the help of advanced biomarker detection technologies. In our latest webinar, learn how these innovations are driving earlier discoveries and improving diagnostics as Mingwei Zhao, Sr. Director of Accelerator Services at Quanterix, explores the science aiding these breakthroughs. https://bit.ly/4de0paU

The study of brain health is evolving rapidly, with blood biomarkers playing a key role in advancing our understanding o...
11/27/2024

The study of brain health is evolving rapidly, with blood biomarkers playing a key role in advancing our understanding of neurological disorders like Alzheimer’s, MS, TBI, and more. 🧠

Blood biomarkers such as p-Tau 217, brain-derived Tau (BD-Tau), Neurofilament light chain (NfL), and glial fibrillary protein (GFAP) offer valuable insights into neurodegeneration and neuroinflammation, enabling more precise research and potential for early detection.

Quanterix has compiled a comprehensive brochure on Simoa® assays tailored for CNS diseases and neurological conditions, highlighting key blood biomarkers and their applications in research. Whether you’re exploring neurodegeneration or brain injury, this resource can provide insights on tools used to measure and analyze critical neurological biomarkers

📄 Explore the full brochure: https://bit.ly/4g8at6P

Biomarkers offer a promising path toward advancing cancer detection and treatment. Simoa® technology provides ultra-sens...
11/27/2024

Biomarkers offer a promising path toward advancing cancer detection and treatment. Simoa® technology provides ultra-sensitive measurements of key cancer biomarkers, supporting research driving progress in early detection, personalized therapy, and disease monitoring.

Explore peer-reviewed studies showcasing these breakthroughs. ⬇️

Curious how biomarkers are driving neurology research? Join us for an afternoon of discovery and insight with field expe...
11/22/2024

Curious how biomarkers are driving neurology research? Join us for an afternoon of discovery and insight with field experts from across North America at the upcoming Simoa® Success Seminar. This virtual session will feature the latest advancements driven by biomarker detection, including:

➡️ Blood biomarkers in multiple sclerosis: Bridging clinical and research insights with Dr. Ahmed Abdelhak, University of California, San Francisco

➡️ Brain-derived extracellular vesicles and neurodegeneration: Led by Dr. Aurelie Ledreux, University of Colorado, Anschutz Medical Campus

➡️ Neurological biomarkers and health insights: Dr. Sophie Stukas and Jennifer Cooper, University of British Columbia

Don’t miss this opportunity to hear these experts as they share their research and applications. Expand your knowledge and register today: https://bit.ly/48QjsaG

Inflammatory mediators, like cytokines, offer important insights into understanding neurological disorders, from TBIs to...
11/21/2024

Inflammatory mediators, like cytokines, offer important insights into understanding neurological disorders, from TBIs to neurodegenerative diseases. Explores how Simoa® Cytokine Advantage PLUS offers ultra-sensitive solutions to propel neuroinflammation research. ➡️ https://bit.ly/4hX39Ng

11/20/2024

Chemotherapy-induced peripheral neuropathy (CIPN) affects many patients, causing symptoms from sensitivity to touch and numbness to neuropathic pain. CIPN has traditionally been challenging to assess objectively. Our most recent webinar explores the potential of neurofilament light chain (NfL) as a reliable biomarker to measure CIPN with greater accuracy.

Join us for expert insights from Tore B. Stage, Head of Research at the University of Southern Denmark, and dive into the science to learn how advanced NfL detection technology is making strides in CIPN research.

Watch Now: https://bit.ly/3NtUbca

11/13/2024

Thank you to everyone who joined us at the Simoa® Success Seminar in Budapest! We had an incredible time diving into the latest in Simoa technology with technical deep dives and expert-led workshops from leading minds in the biomarker field.

Throughout the week, we explored important topics, including NfL and GFAP reference databases in large-scale studies, research measuring extracellular vesicle subpopulations, and the detection of IFN subtypes in translational and clinical research.

Here’s to more opportunities for learning, collaboration, and advancement in biomarker research!

Save the Date! On December 5, the Simoa® Success Seminar is crossing the Atlantic—from Budapest to North America! 🌍Join ...
11/13/2024

Save the Date! On December 5, the Simoa® Success Seminar is crossing the Atlantic—from Budapest to North America! 🌍

Join us from anywhere in North America virtually on December 5, 2024, to dive into the latest in biomarker detection, covering neurological biomarkers, translational research in MS, and more.
Save your spot: https://bit.ly/48QjsaG

In recognition of Veterans Day, we invited our team members to share personal notes of gratitude for the veterans in the...
11/11/2024

In recognition of Veterans Day, we invited our team members to share personal notes of gratitude for the veterans in their lives. We’re touched by their heartfelt messages and proud to share some of them here as a tribute to all who have served.

Today, we honor the courageous individuals who have served to protect our freedoms. As part of our recognition, Quanterix is proud to support Home Base, a veteran-focused organization founded by Massachusetts General Hospital and the Boston Red Sox.

To all veterans – thank you for your commitment, service, and sacrifice.

Address

900 Middlesex Turnpike
Billerica, MA
01821

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+16173019400

Website

Alerts

Be the first to know and let us send you an email when Quanterix posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Quanterix:

Shortcuts

Share

Category